BioLineRx’s (BLRX) Buy Rating Reaffirmed at HC Wainwright

BioLineRx (NASDAQ:BLRX)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock.

Separately, StockNews.com started coverage on BioLineRx in a research report on Thursday, October 31st. They set a “hold” rating for the company.

BioLineRx Stock Performance

Shares of NASDAQ BLRX opened at $0.45 on Wednesday. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The stock’s fifty day moving average price is $0.53 and its two-hundred day moving average price is $0.63. BioLineRx has a one year low of $0.39 and a one year high of $1.93. The firm has a market cap of $36.08 million, a price-to-earnings ratio of -1.00 and a beta of 1.48.

BioLineRx (NASDAQ:BLRX) last released its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $5.39 million for the quarter, compared to the consensus estimate of $3.93 million. On average, equities analysts forecast that BioLineRx will post -0.25 EPS for the current year.

Institutional Trading of BioLineRx

Institutional investors and hedge funds have recently modified their holdings of the business. PVG Asset Management Corp bought a new stake in shares of BioLineRx during the 2nd quarter worth $70,000. Atria Investments Inc lifted its position in shares of BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC bought a new stake in shares of BioLineRx during the 2nd quarter worth $462,000. 1.56% of the stock is currently owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.